Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | SNCA | P37840 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 3/20 | 0.35 |
| ▸ | PIM1 | P11309 | 2/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16268323 | 0.81 | ADAMTS5 (0.43) | RETCES1SNCAL3MBTL1NOX1 | |
| SCHEMBL16268277 | 0.78 | CBFB (0.44) | CES1SNCAL3MBTL1NOX1MEN1 | |
| SCHEMBL7692247 | 0.68 | SNCA (0.45) | RETCES1SNCAL3MBTL1NOX1 | |
| SCHEMBL6752830 | 0.68 | MAOB (0.66) | CES1LMNAMAOAMAOB | |
| SCHEMBL16268777 | 0.67 | CES1 (0.43) | RETCES1SNCAL3MBTL1NOX1 | |
| SCHEMBL16268200 | 0.67 | CES1 (0.43) | RETCES1SNCAMEN1GAA | |
| SCHEMBL7388354 | 0.66 | KIF11 (0.48) | CES1MAPTHTTLRRK2PIM1 | |
| SCHEMBL16268613 | 0.66 | CES1 (0.42) | RETCES1SNCAMEN1MAPT | |
| SCHEMBL16268700 | 0.66 | CES1 (0.42) | CES1SNCAMEN1GAAMAPT | |
| SCHEMBL16268703 | 0.65 | CES1 (0.37) | RETCES1SNCAMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004118-B1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | ARANDA PHARMA LTD (FI) | 2018-12-19 | — | — | EP | claimed |
| US-9827249-B2 | Use of condensed benzo[B]thiazine derivatives as cytoprotectants | ARANDA PHARMA LTD (FI) | 2017-11-28 | — | — | US | claimed |
| US-20160106754-A1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | ARANDA PHARMA LTD (FI) | 2016-04-21 | — | — | US | claimed |
| EP-3004118-A1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | Aranda Pharma Ltd (FI) | 2016-04-13 | — | — | EP | claimed |
| WO-2014191632-A1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | MEDEIA THERAPEUTICS LTD (FI) | 2014-12-04 | — | — | WO | claimed |
| EP-3004118-B1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | ARANDA PHARMA LTD (FI) | 2018-12-19 | — | — | EP | disclosed |
| US-9827249-B2 | Use of condensed benzo[B]thiazine derivatives as cytoprotectants | ARANDA PHARMA LTD (FI) | 2017-11-28 | — | — | US | disclosed |
| US-9827249-B2 | Use of condensed benzo[B]thiazine derivatives as cytoprotectants | ARANDA PHARMA LTD (FI) | 2017-11-28 | — | — | US | disclosed |
| US-20160106754-A1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | ARANDA PHARMA LTD (FI) | 2016-04-21 | — | — | US | disclosed |
| US-20160106754-A1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | ARANDA PHARMA LTD (FI) | 2016-04-21 | — | — | US | disclosed |
| EP-3004118-A1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | Aranda Pharma Ltd (FI) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014191632-A1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | MEDEIA THERAPEUTICS LTD (FI) | 2014-12-04 | — | — | WO | disclosed |
| WO-2014191632-A1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | MEDEIA THERAPEUTICS LTD (FI) | 2014-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160106754-A1 | USE OF CONDENSED BENZO[B]THIAZINE DERIVATIVES AS CYTOPROTECTANTS | TXN2, GPX4, NQO1 | RET 3248/4885CES1 513/4885SNCA 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.